Shandong Luye Drug Patent Portfolio
Shandong Luye owns 1 orange book drug protected by 5 US patents Given below is the list of Shandong Luye's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10098882 | Risperidone sustained release microsphere composition | 10 Apr, 2032 | Active |
| US10406161 | Risperidone sustained release microsphere composition | 10 Apr, 2032 | Active |
| US11110094 | Risperidone sustained release microsphere composition | 10 Apr, 2032 | Active |
| US9446135 | Risperidone sustained release microsphere composition | 10 Apr, 2032 | Active |
| US9532991 | Risperidone sustained release microsphere composition | 10 Apr, 2032 | Active |
Latest Legal Activities on Shandong Luye's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Shandong Luye.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Jul, 2024 | US9532991 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2024 | US9446135 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Mar, 2023 | US10406161 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Mar, 2022 | US10098882 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Sep, 2021 | US11110094 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Sep, 2021 | US11110094 |
|
Email Notification
Critical
| 19 Aug, 2021 | US11110094 |
|
Issue Notification Mailed
Critical
| 18 Aug, 2021 | US11110094 |
| Dispatch to FDC | 05 Aug, 2021 | US11110094 |
|
Application Is Considered Ready for Issue
Critical
| 05 Aug, 2021 | US11110094 |
|
Issue Fee Payment Verified
Critical
| 04 Aug, 2021 | US11110094 |
|
Issue Fee Payment Received
Critical
| 04 Aug, 2021 | US11110094 |
|
Email Notification
Critical
| 05 May, 2021 | US11110094 |
|
Mail Notice of Allowance
Critical
| 05 May, 2021 | US11110094 |
|
Electronic Review
Critical
| 05 May, 2021 | US11110094 |
Shandong Luye Drug Patents' Oppositions Filed in EPO
Shandong Luye drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 20, 2017, by Lecomte & Partners. This opposition was filed on patent number EP12777430A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP19176691A | Jul, 2021 | Alkermes Pharma Ireland Limited | Opposition rejected |
| EP16179390A | Apr, 2020 | Alkermes Pharma Ireland Limited | Opposition rejected |
| EP16179390A | Apr, 2020 | Aera A/S | Opposition rejected |
| EP12777430A | Jun, 2017 | Lecomte & Partners | Opposition rejected |
Shandong Luye's Family Patents
Shandong Luye Drug List
Given below is the complete list of Shandong Luye's drugs and the patents protecting them.
1. Rykindo
Rykindo is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10098882 | Risperidone sustained release microsphere composition |
10 Apr, 2032
(7 years from now)
| Active |
| US10406161 | Risperidone sustained release microsphere composition |
10 Apr, 2032
(7 years from now)
| Active |
| US11110094 | Risperidone sustained release microsphere composition |
10 Apr, 2032
(7 years from now)
| Active |
| US9446135 | Risperidone sustained release microsphere composition |
10 Apr, 2032
(7 years from now)
| Active |
| US9532991 | Risperidone sustained release microsphere composition |
10 Apr, 2032
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rykindo's drug page